Timothy Yap

Timothy Yap is a leader in biomarker-driven early-phase clinical trials who has pioneered the integration of MRD endpoints into novel therapeutic development, particularly for DNA damage response-targeted agents. His work designing MRD-guided clinical trials has established new paradigms for using ctDNA clearance as a surrogate endpoint for accelerated drug approval in solid tumors. He leads multiple international studies investigating how MRD status can guide therapy escalation and de-escalation decisions.